Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Akero Therapeutics (AKRO – Research Report ... that highlight the promising potential of Akero Therapeutics’ lead product candidate, ...
Akero Therapeutics (AKRO – Research Report) received a Buy rating and a $65.00 price target from Phillip Securities analyst Jonathan Woo today. The company’s shares closed last Friday at $28.09. Don't ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback